| Literature DB >> 28589416 |
Pei-Feng Zhu1,2,3, Zhi Dai2,4, Bei Wang1,2,3, Xin Wei1,2,3, Hao-Fei Yu1,2,3, Zi-Ru Yan1,2,3, Xu-Dong Zhao4, Ya-Ping Liu5,6, Xiao-Dong Luo7,8.
Abstract
Four new phenolic amides, 4-O-methylgrossamide (1), (E)-2-(4,5-dihydroxy-2-{3-[(4-hydroxyphenethyl)amino]-3-oxopropyl}-phenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)acryl-amide (2), (Z)-lyciumamide C (3), (Z)-thoreliamide B (4), together with thirteen known phenolic amides were identified from the stem of Lycium barbarum. The structures of the new compounds were determined by spectroscopic methods. All compounds were evaluated for their anti-cancer activities against human glioma stem cell lines.Entities:
Keywords: Anticancer activities; Glioma stem cell; Lycium barbarum; Phenolic amides
Year: 2017 PMID: 28589416 PMCID: PMC5709248 DOI: 10.1007/s13659-017-0134-x
Source DB: PubMed Journal: Nat Prod Bioprospect ISSN: 2192-2209
Fig. 1Structures of compounds 1–17
1H (600 MHz) and 13C NMR (150 MHz) Data for compounds 1, 2 in DMSO-d 6 and 4 in CD3OD (δ in ppm, J in Hz)
| No. |
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 132.1 | 126.5 | 130.1 | |||
|
| 6.94 d (2.0) | 109.6 | 6.39 d (2.0) | 112.4 | 7.21 d (2.1) | 119.0 |
|
| 148.9 | 147.4 | 144.8 | |||
|
| 149.0 | 146.9 | 145.6 | |||
|
| 6.98 d (8.4) | 111.7 | 6.66 d (8.3) | 115.2 | 6.92 d (8.4) | 117.8 |
|
| 6.85 dd (8.4, 2.0) | 118.4 | 6.73 dd (8.3, 2.0) | 124.7 | 6.98 dd (8.4, 2.1) | 124.5 |
|
| 5.93 d (8.1) | 87.5 | 7.57 s | 135.0 | 6.63 d (12.6) | 137.2 |
|
| 4.23 d (8.1) | 56.0 | 125.6 | 5.88 d (12.6) | 123.3 | |
|
| 169.4 | 166.8 | 170.4 | |||
|
| 3.78 s | 55.7 | 3.37 s | 54.6 | ||
|
| 3.76 s | 55.5 | ||||
|
| 128.6 | 130.7 | 128.6 | |||
|
| 7.16 d (1.6) | 111,.7 | 6.52 s | 116.7 | 6.70 br. s | 106.0 |
|
| 144.1 | 144.4 | 149.5 | |||
|
| 148.7 | 145.5 | 137.7 | |||
|
| 128.4 | 6.80 s | 116.6 | 149.5 | ||
|
| 6.91 s | 115.9 | 131.4 | 6.70 br. s | 106.0 | |
|
| 7.38 d (15.7) | 138.7 | 2.51 m | 27.9 | 4.88 d (8.1) | 78.0 |
|
| 6.49 d (15.7) | 119.7 | 2.13 td (9.4, 6.5) | 36.0 | 4.07 ddd (8.1, 4.3, 2.5) | 80.3 |
|
| 165.2 | 171.4 | 3.71 dd (12.5, 2.5) | 62.2 | ||
|
| 3.85 s | 55.7 | 3.75 s | 56.9 | ||
|
| 129.7 | 129.6 | 131.3 | |||
|
| 7.04 d (8.4) | 129.6 | 6.94 d (8.4) | 129.5 | 6.98 d (8.4) | 130.8 |
|
| 6.71 d (8.4) | 115.2 | 6.68 d (8.4) | 115.1 | 6.67 d (8.4) | 116.4 |
|
| 155.7 | 155.7 | 157.1 | |||
|
| 6.71 d (8.4) | 115.2 | 6.68 d (8.4) | 115.1 | 6.67 d (8.4) | 116.4 |
|
| 7.04 d (8.4) | 129.6 | 6.94 d (8.4) | 129.5 | 6.98 d (8.4) | 130.8 |
|
| 2.67 t (5.1) | 34.4 | 2.66 t (7.5) | 34.6 | 2.68 t (7.6) | 35.5 |
|
| 3.36 t (5.1) | 40.9 | 3.41 t (7.5) | 41.5 | 3.41 m | 42.5 |
|
| 129.3 | 129.6 | ||||
|
| 7.01 d (8.5) | 129.5 | 6.91 d (8.4) | 129.4 | ||
|
| 6.69 d (8.5) | 115.1 | 6.65 d (8.4) | 115.1 | ||
|
| 155.7 | 155.6 | ||||
|
| 6.69 d (8.5) | 115.1 | 6.65 d (8.4) | 115.1 | ||
|
| 7.01 d (8.5) | 129.5 | 6.91 d (8.4) | 129.4 | ||
|
| 2.67 t (5.1) | 34.2 | 2.58 t (7.4) | 34.5 | ||
|
| 3.36 t (5.1) | 40.8 | 3.20 t (7.4) | 40.7 | ||
Fig. 3Key ROESY () correlations of compounds 1–4
Fig. 2Key 1H–1H COSY () and HMBC () correlations for compounds 1–4
1H (500 MHz) and 13C NMR (125 MHz) Data for compounds 3 and 6 in DMSO-d 6 and CD3OD (δ in ppm, J in Hz)
| No. | 3 (in DMSO- | 3 (in CD3OD) | 6 (in DMSO- | 6 (in CD3OD) | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
| 128.7 | 130.5 | 128.5 | 130.8 | ||||
|
| 7.60 s | 114.4 | 7.22 d (1.7) | 115.4 | 7.10 s | 111.9 | 7.07 d (1.5) | 113.2 |
|
| 142.9 | 145.2 | 143.9 | 145.7 | ||||
|
| 148.1 | 150.2 | 149.0 | 151.3 | ||||
|
| 128.7 | 129.9 | 130.1 | 130.2 | ||||
|
| 7.23 s | 119.7 | 7.05 s | 120.2 | 7.16 s | 116.6 | 7.12 s | 116.2 |
|
| 6.55 d (12.9) | 136.7 | 6.66 d (12.6) | 138.5 | 7.38 d (15.7) | 139.1 | 7.46 d (15.7) | 141.9 |
|
| 5.81 d (12.9) | 121.5 | 5.85 d (12.6) | 122.3 | 6.50 d (15.7) | 119.4 | 6.42 d (15.7) | 119.7 |
|
| 166.2 | 170.3 | 165.4 | 169.0 | ||||
|
| 3.73 s | 55.6 | 3.78 s | 56.5 | 3.73 s | 55.6 | 3.80 s | 56.4 |
|
| 132.2 | 134.5 | 132.0 | 134.1 | ||||
|
| 6.90 s | 110.3 | 6.93 d (2.0) | 110.6 | 6.94 s | 110.4 | 6.93 d (2.0) | 110.5 |
|
| 147.6 | 149.2 | 147.7 | 149.1 | ||||
|
| 146.4 | 147.7 | 146.6 | 147.7 | ||||
|
| 6.75 s | 115.3 | 6.75 d (8.1) | 116.3 | 6.79 s | 115.4 | 6.77 d (8.2) | 116.2 |
|
| 6.75 s | 118.5 | 6.81 dd (8.1, 2.0) | 119.8 | 6.79 s | 118.8 | 6.81 dd (8.2,2.0) | 118.5 |
|
| 5.50 d (6.5) | 87.6 | 5.56 d (6.2) | 89.7 | 5.52 d (6.9) | 87.7 | 5.55 d (6.4) | 89.7 |
|
| 3.46 d (6.5) | 52.8 | 3.41 d (5.8) | 55.2 | 3.49 d (6.9) | 52.7 | 3.45 dd (8.0,6.7) | 54.8 |
|
| 3.61 dd (10.6,7.2) | 63.1 | 3.82 d (4.8) | 64.9 | 3.71 dd (10.6,6.0) | 62.8 | 3.83 d (5.2) | 64.6 |
| 3.69 dd (10.6,4.8) | 3.75 d (6.1) | 3.69 dd (10.6,4.8) | ||||||
|
| 3.76 s | 55.6 | 3.85 s | 56.8 | 3.77 s | 55.7 | 3.87 s | 56.7 |
|
| 129.5 | 131.3 | 129.5 | 131.2 | ||||
|
| 6.98 d (8.5) | 129.4 | 6.96 d (8.4) | 130.8 | 7.04 d (8.6) | 129.6 | 7.04 d (8.4) | 130.7 |
|
| 6.67 d (8.4) | 115.1 | 6.68 d (8.5) | 116.4 | 6.71 d (8.4) | 115.2 | 6.71 d (8.5) | 116.3 |
|
| 155.6 | 157.1 | 155.7 | 156.9 | ||||
|
| 6.67 d (8.4) | 115.1 | 6.68 d (8.5) | 116.4 | 6.71 d (8.4) | 115.2 | 6.71 d (8.5) | 116.3 |
|
| 6.98 d (8.5) | 129.4 | 6.96 d (8.4) | 130.8 | 7.04 d (8.6) | 129.6 | 7.04 d (8.4) | 130.7 |
|
| 2.61 t (7.5) | 34.2 | 2.65 t (7.5) | 35.9 | 2.67 t (7.4) | 34.4 | 2.74 t (7.3) | 35.8 |
|
| 3.26 t (7.5) | 40.6 | 3.31 t (7.5) | 42.5 | 3.35 t (7.4) | 40.8 | 3.45 t (7.3) | 42.5 |
Fig. 4Compounds 1–5 against human glioma stem cells by phenotypic screening; a Compound 5 against GSC-3# and GSC-12# at 10 μg/mL; b Compounds 1–4 against GSC-12# at 25 μg/mL
Fig. 5The IC50 value for compounds 1 and 5 against human glioma stem cell lines